APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer and related conditions. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs 27 people and is led by a management team with strong background in drug development, especially in cancer immunotherapy.
Apeiron has a portfolio of innovative projects, five of which are in clinical development. Its lead project APN311 is currently being investigated in several late-stage clinical trials against high-risk neuroblastoma (a rare childhood cancer).
See projects for the present status of Apeiron's portfolio.
Apeiron today announced the signing of two transactions as part of the worldwide commercialization of APN311, an antibody-based immunotherapy in development for the treatment of children suffering from high-risk neuroblastoma.